Discovery reveals role of EGFR in resistance to KRAS inhibitors in pancreatic cancer

A study led by University of Cincinnati Cancer Center researchers sheds new light on how pancreatic cancer cells resist ...
Targeted Oncology

Rolling NDA Submission Begins for Zipalertinib in EGFR Exon 20+ NSCLC

Zipalertinib's NDA submission is based on promising efficacy data from the REZILIENT1 trial, showing a 35.2% ORR and ...
The American Journal of Managed Care

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...
Hoodline

University of Cincinnati Crusaders Unravel Pancreatic Cancer's Shield Against Treatment in Groundbreaking Study

Study at University of Cincinnati reveals why pancreatic cancer cells resist KRAS inhibitors, suggesting EGFR blocking could ...
ascopubs.org

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer

High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma ...
KOIN 6

Treatment with RYBREVANT® (amivantamab-vmjw) and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated ...

"Often, patients with EGFR-mutated NSCLC develop resistance to treatment during the course of therapy. Resistance in patients is typically diverse and polyclonal, meaning their tumors can have more ...
KRQE Blogs

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

Lung cancer is the leading cause of cancer mortality worldwide, resulting in 1.8 million deaths each year, with NSCLC accounting for 80 to 85 percent of all cases. 3,4 Of patients with EGFR-mutated ...
KTLA

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

SHANGHAI, July 2, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today ...
Clinical Trials Arena on MSN

Race Oncology secures HREC approval for Phase Ia/Ib RC220 trial

"Race Oncology secures HREC approval for Phase Ia/Ib RC220 trial" was originally created and published by Clinical Trials ...
ascopubs.org

Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With ...

Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di ...